Insider and congress filings
CRISPR Therapeutics AG (CRSP)
About CRISPR Therapeutics AG
from the company's filings and listing- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Chief executive
- Samarth Kulkarni
- Employees
- 393
- Listed since
- Oct 19, 2016
- Market value
- $5.2B
- Price to earnings
- -
- Earnings per share
- -$4.67
- Dividend yield
- -
Earnings
6 reported quarters · next on Nov 9, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q2 FY2026reported Aug 3, 2026 | -$0.94 | -$1.19 | $10.2M | $7.4M | EPS beatRevenue beat |
| Q1 FY2026reported May 4, 2026 | -$1.28 | -$1.19 | $1.5M | $6.1M | EPS missRevenue miss |
| Q4 FY2025reported Feb 12, 2026 | -$1.37 | -$1.15 | $864K | $4.7M | EPS missRevenue miss |
| Q3 FY2025reported Nov 10, 2025 | -$1.17 | -$1.26 | $889K | $9.1M | EPS beatRevenue miss |
| Q2 FY2025reported Aug 5, 2025 | -$2.40 | -$1.47 | $892K | $6.1M | EPS missRevenue miss |
| Q1 FY2025reported May 6, 2025 | -$1.58 | -$1.27 | $865K | $6.0M | EPS missRevenue miss |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| ARK Investment Management LLC | $516.0M | 9,460,939 | -16.4% | 9.80% |
| Blackrock, Inc. | $455.4M | 8,348,977 | +8.7% | 8.65% |
| Orbis Allan Gray Ltd | $297.2M | 5,449,161 | -10.8% | 5.65% |
| Capital World Investors | $259.0M | 4,749,525 | +0.5% | 4.92% |
| State Street Corp | $235.7M | 4,321,666 | +8.5% | 4.48% |
| GSK PLC | $175.7M | 3,220,627 | 0.0% | 3.34% |
| Geode Capital Management, LLC | $136.9M | 2,509,915 | +5.6% | 2.60% |
| T. Rowe Price Investment Management, Inc. | $112.0M | 2,053,017 | -30.5% | 2.13% |
| SR One Capital Management, LP | $111.2M | 2,038,763 | 0.0% | 2.11% |
| Two Sigma Investments, LP | $108.5M | 1,988,621 | +34.1% | 2.06% |
| FMR LLC | $104.1M | 1,908,503 | -2.4% | 1.98% |
| Sumitomo Mitsui Trust Group, Inc. | $93.8M | 1,720,734 | -7.2% | 1.78% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Open-market insider trades
3 filings of 24 on record| Insider | Action | Shares | Price | Value | Trade date | Delay |
|---|---|---|---|---|---|---|
| Naimish PatelChief Medical Officer | Sold | 3,786 | $55.62 | $211K | May 29, 2026 | 3d |
| Samarth KulkarniChief Executive Officer | Sold | 10,020 | $46.78 | $469K | Mar 23, 2026 | 1d |
| James R. KasingerGeneral Counsel and Secretary | Sold | 3,182 | $46.78 | $149K | Mar 23, 2026 | 1d |
One row is one filing. A filing that reported its trade in several tranches is summed, priced at the weighted average, and marked with its line count.
Congress trades in CRSP
3 disclosures · median 29d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Thomas R. Suozzi | Stock | Sale | $50,001 - $100,000 | -53.8%S&P +75.3% · vs S&P 500 -129.1% | Sep 20, 2021 | Oct 5, 2021 | 15d |
| Thomas R. SuozziFiled late | Stock | Purchase | $50,001 - $100,000 | -51.0%S&P +82.3% · vs S&P 500 -133.3% | Jun 3, 2021 | Sep 23, 2021 | 112d |
| Marjorie Taylor GreeneJoint | Stock | Purchase | $1,001 - $15,000 | -71.1%S&P +98.5% · vs S&P 500 -169.6% | Jan 21, 2021 | Feb 19, 2021 | 29d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
A congressional disclosure names a company by its ticker symbol alone, and a symbol can be reassigned after its previous holder leaves the market. One disclosure filed under CRSP is dated before this company began trading under it, and is not shown here.
Awards, option exercises and gifts (19)
| Insider | Event | Shares | Date |
|---|---|---|---|
| Raju PrasadChief Financial Officer | Gift | 750 | Aug 7, 2026 |
| Harold Edward FlemingDirector | Stock award | 13,000 | Jun 5, 2026 |
| John GreeneDirector | Stock award | 13,000 | Jun 5, 2026 |
| Ali BehbahaniDirector | Stock award | 13,000 | Jun 5, 2026 |
| Simeon GeorgeDirector | Stock award | 13,000 | Jun 5, 2026 |
| Maria FardisDirector | Stock award | 13,000 | Jun 5, 2026 |
| Katherine A. HighDirector | Stock award | 13,000 | Jun 5, 2026 |
| Douglas A. TrecoDirector | Stock award | 13,000 | Jun 5, 2026 |
| Christian RommelDirector | Stock award | 13,000 | Jun 5, 2026 |
| Sandesh MahatmeDirector | Stock award | 13,000 | Jun 5, 2026 |
| Briggs MorrisonDirector | Stock award | 13,000 | Jun 5, 2026 |
| James R. KasingerGeneral Counsel and Secretary | Stock award | 17,000 | May 29, 2026 |
| Raju PrasadChief Financial Officer | Stock award | 19,500 | May 29, 2026 |
| Naimish PatelChief Medical Officer | Stock award | 22,000 | May 29, 2026 |
| Naimish PatelChief Medical Officer | Option exercise | 10,000 | May 28, 2026 |
| James R. KasingerGeneral Counsel and Secretary | Stock award | 63,499 | Mar 20, 2026 |
| Samarth KulkarniChief Executive Officer | Stock award | 196,124 | Mar 20, 2026 |
| Samarth KulkarniChief Executive Officer | Option exercise | 19,687 | Mar 20, 2026 |
| James R. KasingerGeneral Counsel and Secretary | Option exercise | 6,250 | Mar 20, 2026 |
Awards, option exercises, shares withheld to cover tax and gifts all file on the same form as a purchase or a sale. None of them is a decision to trade, so they sit here rather than beside the ones that are.
Questions
Are insiders buying or selling CRSP?
Across the 3 most recent open-market filings shown here, 0 were purchases and 3 were sales.
Which members of Congress have traded CRSP?
Thomas R. Suozzi, Marjorie Taylor Greene disclosed CRSP transactions in the filings shown here.
How quickly are CRSP trades disclosed?
Insider filings on this page reached the public a median of 1 days after the transaction, against the two business days Form 4 allows. Congressional disclosures took a median of 29 days, against the 45 the STOCK Act allows.
How to read a Form 4
A DECISION THE INSIDER MADE
COMPENSATION PLUMBING
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.